Targeting antigens to antigen presenting cells.
Antigen may be targeted to antigen presenting cells (APC) by conjugating the antigen to monoclonal antibodies directed against surface molecules on APC. By now several laboratories have shown that immunotargeting enhances humoral responses, depending upon the targeted ligand or cell type, with low doses of antigen and without the use of adjuvants. There is also preliminary evidence that the method may be used to bias immune responses in desired directions, possibly also to induce tolerance. In addition to its use as an experimental tool for exploring immune reactions the method could in the future also be clinically important, e.g. in vaccination. In this article we give a brief account on work so far published with this novel method and discuss possible mechanisms behind its immunopotentiating effects.
Fossum
S
S
Department of Anatomy, University of Oslo, Norway.
Berg
S F
SF
Mjaaland
S
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000918:Antibody Specificity; D000938:Antigen-Presenting Cells / Q000276:immunology*; D000941:Antigens / Q000008:administration & dosage* / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D008024:Ligands; D051379:Mice; D051381:Rats
D000911:Antibodies, Monoclonal; D000941:Antigens; D000954:Antigens, Surface; D000949:Histocompatibility Antigens Class II; D008024:Ligands